InMed Pharmaceuticals Inc.
INM · NASDAQ
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Market Cap | $3,172 | $3,833 | $4,534 | $13,178 |
| - Cash | $11,122 | $8,988 | $11,807 | $7,953 |
| + Debt | $744 | $1,317 | $519 | $1,022 |
| Enterprise Value | -$7,206 | -$3,838 | -$6,754 | $6,247 |
| Revenue | $4,943 | $4,598 | $4,136 | $1,089 |
| % Growth | 7.5% | 11.2% | 279.6% | – |
| Gross Profit | $1,707 | $1,101 | $1,403 | $544 |
| % Margin | 34.5% | 23.9% | 33.9% | 49.9% |
| EBITDA | -$7,256 | -$7,064 | -$7,783 | -$13,280 |
| % Margin | -146.8% | -153.6% | -188.2% | -1,219% |
| Net Income | -$8,162 | -$7,676 | -$7,948 | -$18,600 |
| % Margin | -165.1% | -166.9% | -192.2% | -1,707.3% |
| EPS Diluted | -11.44 | -27.55 | -86 | -21,350.51 |
| % Growth | 58.5% | 68% | 99.6% | – |
| Operating Cash Flow | -$7,767 | -$6,986 | -$7,283 | -$15,584 |
| Capital Expenditures | $0 | -$9 | -$162 | -$39 |
| Free Cash Flow | -$7,767 | -$6,995 | -$7,445 | -$15,623 |